Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$169.25

2.81 (1.69%)

07:11
01/08/18
01/08
07:11
01/08/18
07:11

Sage Therapeutics to provide pipeline update at JPMorgan Healthcare Conference

Sage Therapeutics announced that in a corporate presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CEOJeff Jonas, M.D., will discuss several components of the company's strategy to build the business for the long term by assembling the capabilities to fully develop and commercialize important medicines. His remarks will highlight three key areas of focus in the pursuit of new classes of CNS therapies: impacting novel, fundamental brain mechanisms; addressing treatment gaps with differentiated therapies; and discovering a potentially groundbreaking approach to depressive disorders. Dr. Jonas will provide additional detail on the following development programs: Brexanolone: Sage is currently focused on launch readiness and building commercial infrastructure to ensure successful commercial execution, if Sage's proprietary formulation brexanolone is approved to address postpartum depression, a common biological complication of childbirth. SAGE-217 and SAGE-324: Sage's novel, oral, next-generation positive allosteric modulators of synaptic and extra-synaptic GABAA receptors. GABA Discovery Programs: Evaluating a series of novel GABAA receptor modulators in pre-clinical development, including SAGE-689, SAGE-105, and others. NMDA Programs: Sage's novel, oral, first-in-class oxysterol-based positive allosteric modulators of the NMDA receptor. The company recently selected SAGE-904 as its second NMDA receptor positive allosteric modulator product candidate for development. Positive modulation of NMDA receptors may have potential in the treatment of a range of neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms. Sage ended 2017 with approximately $518M of cash, cash equivalents and marketable securities, including $325.7M in net proceeds from a public offering completed in November 2017. Based on its current operating plans, Sage expects that its operating expenses will increase year over year in 2018 to support continued pipeline advancement and potential product commercialization of brexanolone in PPD. Sage expects to provide specific 2018 financial guidance in Q4 and FY17 financial results announcement in February 2018.

  • 08

    Jan

SAGE Sage Therapeutics
$169.25

2.81 (1.69%)

12/08/17
RHCO
12/08/17
NO CHANGE
Target $178
RHCO
Buy
Sage Therapeutics price target raised to $178 from $116 at SunTrust
SunTrust analyst Edward Nash raised his price target on Sage Therapeutics to $178 after its positive Phase 2 trial results for SAGE-217 for moderate to severe major depressive disorder. Nash says the findings demonstrate that "rapid onset of action and durability are key differentiators for SAGE-217", also adding that safety is not a concern for the drug based on the clinical studies of both brexanolone and SAGE-217 so far. The analyst has also increased his probability of success estimates for SAGE-217 from 30% to 60% in major depressive disorder cases and from 50% to 60% in post-partum depression cases.
12/08/17
NEED
12/08/17
NO CHANGE
Target $193
NEED
Buy
Sage Therapeutics price target raised to $193 from $100 at Needham
Needham analyst Danielle Brill raised her price target on Sage Therapeutics to $193 following positive Phase 2 results of SAGE-217 in major depressive disorder cases. Brill says that given the "clear and consistent benefit" of the treatment, she has "increased confidence that '217 may have utility in a broad spectrum of mood disorders". In addition to reaching "blockbuster status", the analyst contends that '217 raises the possibility of a near term M&A approach from big pharma.
12/08/17
RAJA
12/08/17
NO CHANGE
Target $206
RAJA
Strong Buy
Sage Therapeutics price target raised to $206 from $109 at Raymond James
Raymond James analyst Laura Chico raised Sage Therapeutics' price target to $206 following positive Phase 2 results of SAGE-217 in major depressive disorder cases. Chico raised her prior market share and probability of success assumptions, as well as adding credit in postpartum depression and thinks the update de-risks that program. The analyst has a Strong Buy rating on Sage shares.
12/08/17
BMOC
12/08/17
NO CHANGE
Target $203
BMOC
Outperform
Sage Therapeutics price target raised to $203 from $112 at BMO Capital
BMO Capital analyst Gary Nachman raised his price target on Sage Therapeutics to $203 and kept his Outperform rating after releasing Phase 2 SAGE-217 major depressive disorder data that "transforms the company". Nachman says he sees high probability of success for the treatment as it progresses to larger Phase 3 studies and calls it a "game changer" in the very large major depressive disorder / post-partum depression markets. The analyst also says the company remains an "attractive acquisition candidate".

TODAY'S FREE FLY STORIES

CREE

Cree

$36.69

0.4 (1.10%)

12:54
01/23/18
01/23
12:54
01/23/18
12:54
Downgrade
Cree rating change  »

Cree downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

PUBGY

Publicis

$17.85

0.03 (0.17%)

12:50
01/23/18
01/23
12:50
01/23/18
12:50
Hot Stocks
Publicis says undergoing 'destabilization attempt,' rejects allegations »

Publicis Groupe said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$61.67

0.42 (0.69%)

12:50
01/23/18
01/23
12:50
01/23/18
12:50
Options
Call buyers in Merck as shares move higher »

Call buyers in Merck as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 02

    Feb

  • 08

    Feb

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 23

    Oct

12:50
01/23/18
01/23
12:50
01/23/18
12:50
General news
U.S. corporate bond update: the slate is thin with just a couple of issues »

U.S. corporate bond…

BCS

Barclays

$11.68

-0.06 (-0.51%)

12:46
01/23/18
01/23
12:46
01/23/18
12:46
Periodicals
Ex-Barclays banker recorded saying he destroyed key report, Bloomberg says »

Former Barclays top…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.29

-0.16 (-0.30%)

12:43
01/23/18
01/23
12:43
01/23/18
12:43
Hot Stocks
Verizon giving 50 shares to employees following tax reform »

Verizon Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

CBOE

Cboe Global Markets

$134.56

0.68 (0.51%)

12:42
01/23/18
01/23
12:42
01/23/18
12:42
Hot Stocks
Cboe Global Markets recognized in Hong Kong as approved stock exchange »

Cboe Global Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

RIG

Transocean

$11.68

-0.25 (-2.10%)

12:40
01/23/18
01/23
12:40
01/23/18
12:40
Options
Rolling action in Transocean calls »

Rolling action in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$6.30

0.01 (0.16%)

, JPM

JPMorgan

$114.46

0.13 (0.11%)

12:35
01/23/18
01/23
12:35
01/23/18
12:35
Hot Stocks
GoPro falls after Morgan Stanley downgrade cites limited strategic value »

Shares of GoPro (GPRO)…

GPRO

GoPro

$6.30

0.01 (0.16%)

JPM

JPMorgan

$114.46

0.13 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 07

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

MET

MetLife

$53.56

-0.29 (-0.54%)

12:31
01/23/18
01/23
12:31
01/23/18
12:31
Hot Stocks
MetLife issues statement on court decision to dismiss appeal in SIFI litigation »

MetLife chairman,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 12

    Jun

CVE

Cenovus Energy

$10.43

0.04 (0.38%)

12:30
01/23/18
01/23
12:30
01/23/18
12:30
Options
Call buyers in Cenovus Energy as shares tick higher »

Call buyers in Cenovus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$135.52

0.31 (0.23%)

12:28
01/23/18
01/23
12:28
01/23/18
12:28
Technical Analysis
Technical Earnings Preview: United Technologies in uptrend before news »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AGN

Allergan

$187.32

-0.83 (-0.44%)

12:25
01/23/18
01/23
12:25
01/23/18
12:25
Options
Allergan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 06

    Feb

  • 16

    Feb

  • 25

    Mar

12:25
01/23/18
01/23
12:25
01/23/18
12:25
Conference/Events
Leerink healthcare services analysts hold an analyst/industry conference call »

Healthcare Services…

VZ

Verizon

$53.23

-0.235 (-0.44%)

12:22
01/23/18
01/23
12:22
01/23/18
12:22
Periodicals
Verizon giving employees 50 shares of restricted stock, CNBC reports »

CNBC's David Faber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

CHFN

Charter Financial

$18.13

-0.12 (-0.66%)

12:21
01/23/18
01/23
12:21
01/23/18
12:21
Hot Stocks
Charter Financial raises quarterly dividend to 8c per share from 5c »

Charter Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$36.96

0.7 (1.93%)

, FOXA

21st Century Fox

$37.31

0.66 (1.80%)

12:20
01/23/18
01/23
12:20
01/23/18
12:20
Hot Stocks
21st Century Fox 'welcomes' part of CMA finding, 'disappointed' about plurality »

21st Century Fox (FOXA)…

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

SKYAY

Sky

$55.97

0.72 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 07

    Feb

$NSD

NASDAQ Market Internals

12:17
01/23/18
01/23
12:17
01/23/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

, AMZN

Amazon.com

$1,327.31

32.73 (2.53%)

12:16
01/23/18
01/23
12:16
01/23/18
12:16
Hot Stocks
Netflix's 'Mudbound' gets four Oscar noms, Amazon's 'The Big Sick' gets nod »

Films produced by Netflix…

NFLX

Netflix

$227.58

7.12 (3.23%)

AMZN

Amazon.com

$1,327.31

32.73 (2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 01

    Feb

  • 18

    Mar

$NYE

NYSE Market Internals

12:16
01/23/18
01/23
12:16
01/23/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$16.46

0.41 (2.55%)

12:15
01/23/18
01/23
12:15
01/23/18
12:15
Options
Hewlett Packard Enterprise put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

, TRV

Travelers

$145.27

5.92 (4.25%)

12:10
01/23/18
01/23
12:10
01/23/18
12:10
General news
On The Fly: Top stock stories at midday »

Stocks opened little…

NFLX

Netflix

$227.58

7.12 (3.23%)

TRV

Travelers

$145.27

5.92 (4.25%)

VZ

Verizon

$53.31

-0.15 (-0.28%)

JNJ

Johnson & Johnson

$143.58

-4.565 (-3.08%)

PG

Procter & Gamble

$89.11

-2.78 (-3.03%)

TSLA

Tesla

$351.56

1.54 (0.44%)

RMD

ResMed

$103.82

16.306 (18.63%)

WHR

Whirlpool

$171.12

4.47 (2.68%)

TWTR

Twitter

$22.96

-0.36 (-1.54%)

INSM

Insmed

$30.86

1.58 (5.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 30

    Jan

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 28

    Feb

  • 08

    Mar

UAL

United Continental

$76.96

0.09 (0.12%)

12:07
01/23/18
01/23
12:07
01/23/18
12:07
Technical Analysis
Technical Earnings Preview: United Continental has a potential bullish pattern »

Heading into earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

RHHBY

Roche

$30.79

0.1 (0.33%)

12:05
01/23/18
01/23
12:05
01/23/18
12:05
Hot Stocks
Roche subsidiary treatment of gastric cancer granted FDA orphan status »

Genentech, a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 23

    Feb

SQ

Square

$44.69

-0.6 (-1.32%)

12:05
01/23/18
01/23
12:05
01/23/18
12:05
Options
Square call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.